anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The passage of weak DC currents across the head (DC polarization) has been done for centuries with various effects reported. Many of the reports and studies of DC effects in humans are, however, archaic, anecdotal, uncontrolled, or scientifically baseless. Recently, it has been shown by objective means, in controlled experiments, that this type of treatment has robust and lasting effects on the excitability of the motor cortex in healthy humans. In vitro and animal experiments have revealed little about the mechanism of this effect, but neither has convincing evidence of toxicity been found at moderate doses. Therefore, we are becoming interested in whether this type of treatment can be used to improve cognitive processing in individuals with brain lesions, particularly of the prefrontal cortex. The purpose of this project is to prepare the way for clinical trials by beginning to establish the safety of this technique in humans and then to look for preliminary evidence of potentially useful effects on cognition when moderate doses are applied to the prefrontal cortex. First, we propose to test the safety of 20 min of anodal and cathodal DC applied the left prefrontal area, at 1 mV, by looking for clinical-level effects on verbal fluency, cognitive processing speed, EEG, mood, or motor reaction speed after exposure. The duration of exposure in this study will match the time required to gather preliminary efficacy data in healthy controls and patients. Then, in a dose-finding study, we propose to find the anodal DC amperage necessary for producing a clear effect on excitability, as measured by an increase in the amplitude of the motor evoked potential to transcranial magnetic stimulation. Then, if no significant adverse effects are in the first two studies, a preliminary efficacy study will look for differences in these measures between groups receiving anodal, cathodal, and sham DC of the left prefrontal cortex during stimulation.
FIELD: cosmetic industry. SUBSTANCE: invention relates to agents for curative-prophylactic skin and hair care. Invention proposes a cosmetic composition containing 5-95 wt.-% of Jerusalem artichoke (Helianthus tuberosum L. ) extracts of the following composition: 0.25-50 wt.-% of Jerusalem artichoke extracts and extractant - the rest. The cosmetic agent involves tuberous and above-ground parts of plant at moisture 0.5-82% in aqueous or aqueous-saline or aqueous-alcoholic extractive media. The cosmetic agent containing Jerusalem artichoke shows correcting effect on systemic immune response of body. EFFECT: broadened assortment of use of Jerusalem artichoke plant and cosmetic preparations of curative-prophylactic effect based on the known cosmetic compositions. 3 cl, 4 tbl, 1 ex
Prepn. of a salt of N-acetylglutamic acid (I) comprises neutralising (I) with a basic cpd. of a divalent metal, pref. Ca(OH)2. Pref. an aq. soln. is prepd., then the salt is pptd. by adding an organic solvent (pref. methanol, ethanol or acetone), recovered and dried at 105 degrees C. Alternatively, the aq. soln. is filtered, filled into containers and sterilised by heating. Other water sol. salts, pref. MgC 12, and >=1 preservative may be added to the soln. Soln. can be given by intravenous or intramuscular injections and infusions in Ca therapy or, when combined with other active ingredients such as Mg salts, in treatment of tetany in ruminants. The Ca salt of (I) is readily soluble in water, has a bland taste, is well tolerated, of low toxicity (i.e. LD50 in mice is 800 mg/kg on Ca basis), readily resorbed and very stable. It requires no toxic auxiliaries such as boric acid.
Inherited forms of cardiac arrhythmias mostly are rare diseases (prevalence <1:2000) and considered to be either "primary electrical heart disorders" due to the absence of structural heart abnormalities or "cardiac ion channel disorders" due to the myocellular structures involved. Precise knowledge of the electrocardiographic features of these diseases and their genetic classification will enable early disease recognition and prevention of cardiac events including sudden cardiac death.The genetic background of these diseases is complex and heterogeneous. In addition to the predominant "private character" of a mutation in each family, locus heterogeneity involving many ion channel genes for the same familial arrhythmia syndrome is typical. Founder pathogenic variants or mutational hot spots are uncommon. Moreover, phenotypes may vary and overlap even within the same family and mutation carriers. For the majority of arrhythmias, the clinical phenotype of an ion channel mutation is restricted to cardiac tissue, and therefore, the disease is nonsyndromic.Recent and innovative methods of parallel DNA analysis (so-called next-generation sequencing, NGS) will enhance further mutation and other variant detection as well as arrhythmia gene identification.
An estimated 40,000 new HIV infections occur annually in the United States. Although significant effort has been devoted to improving identification of patients with undiagnosed HIV infection, this rate has changed very little in the last decade and new infections appear to be increasing most in non-traditional risk groups, including racial and ethnic minorities. Most persons infected with HIV still do not get tested until late in their disease courses, primarily due to its long asymptomatic period and their relatively poor access to routine medical care. Over 100 million people visit emergency departments (EDs) annually, and the ED commonly serves as a patient's only source for medical care, and thus the only potential opportunity to receive HIV counseling, testing, and referral (CTR). Also, patients who are most likely to use the ED as their only source of care are often those for whom the HIV epidemic is spreading most. The primary objective of the proposed research is to demonstrate clinical effectiveness, clinical efficiency, cost effectiveness, and patient-staff satisfaction with performing routine voluntary opt-out rapid HIV CTR in a high-volume urban ED, when compared to a targeted rapid HIV CTR program in the same setting. The primary hypothesis of the proposed investigations is that opt-out rapid HIV CTR is associated with a higher rate of overall testing, identification of patients infected with HIV, identification of patients infected with HIV earlier in their disease courses, and successful linkage into medical and preventative care for those patients who test positive for HIV infection. The secondary hypotheses are that opt-out rapid HIV CTR: (1) is not associated with increased ED processes of care, defined by patient waiting times, length of stays, the proportion of patients who leave before completing their evaluations, and an overcrowding index; and (2) is cost-effective. The tertiary hypotheses are that opt-out rapid HIV CTR is associated with a higher level of patient and ED staff satisfaction. To address these hypotheses, we will perform a prospective quasi-experimental equivalent time-samples clinical trial in which consecutive patients who present to the ED during interventional periods will be offered opt-out rapid HIV CTR as part of their visits, and during the control periods, patients will be targeted by physicians for rapid HIV CTR using a previously developed and validated CTR model. The results obtained from this study will improve our understanding of how best to identify patients with HIV infection in ED, and whether opt-out rapid HIV CTR is an effective means to achieve the CDC's goals of identifying more asymptomatic HIV-infected patients earlier in their disease courses.
All patients involved in the study will have a PET scan performed. This involves injecting a small amount of radiolabelled glucose (sugar) into the blood. A scan will then be performed to obtain an image of where in the body that glucose is being used. Patients will also have spirometry done. Spirometry is a simple procedure measuring the functioning of the lungs (FEV-1) by measuring the amount of air a patient can blow out and inhale (the patient breathes into a machine). Bronchoalveolar lavage (BAL) will be performed. This involves putting a small amount of fluid into a section of the lung, then suctioning it out to retrieve the cells and molecules contained in the substance lining the lung.

Subjects will be patients with cystic fibrosis. Ten subjects will be stable with either mild or moderate disease. These subjects will receive a PET scan, spirometry, and BAL.

This portion of the study is made up of 10 stable CF patients, 5 of whom will have mild disease, and 5 of whom will have moderate disease. These patients will receive a PET scan, spirometry and a BAL over 2 consecutive days. On day 1, patients will have a PET scan and spirometry. On day 2, patients will have a BAL.

Patients will arrive on the first day after fasting for at least 6 hours and will be taken to the PET facility. PET scanning consists of a 2-minute scan followed by a 15-minute scan, injection of radiolabelled sugar into the vein, and 66 minutes of scanning. The patient will then be instructed to empty his or her bladder to reduce total radiation exposure. The patient will then be given a meal. Next, the patient will be taken for spirometry, the last test of day 1, which simple involves breathing into a machine that measures the amount of air inhaled and exhaled. Upon reporting to the GCRC on day 2, the patient will be taken for a BAL (the patient will have fasted for at least 6 hours prior to admission). BAL involves a small tube placed into the mouth, down the throat, and into the lung (lidocaine is used to numb the entire area). Less than 3 tablespoons of saline (salt water) is poured down the tube, then immediately sucked back up and collected by the doctor. This is repeated twice, for a total of 8 tablespoons of liquid.
A pre-post interventional study using health talks was carried out among 345 adolescents aged 13 to 20 years. Participants included both male and female students aged 13 to 20 years. Owing to the large number, the students were divided into two groups. The Pre-test was then administered. Following this, two health education sessions were delivered by two registered nurses for each session. A week after these health talks, the research team went back to the school to collect data for the post-intervention. Questionnaires used for both pre and post assessment collected data on demographic factors and knowledge on dietary and physical activity behaviours linked to hypertension.
This group will only take part in the data collection sessions. After the first testing session (Pre-Intervention) the participants will be asked to rest comfortably for 5 minutes. After the rest period, they will be reassessed. Upon completion of the second testing, they will be asked to maintain the same lifestyle over the course of 2 weeks. They will then be asked to return to the lab after the 2 week interval to be tested again. Upon completion of the third testing session, they will be contacted after 1 month to complete the self-reported function questionnaires.
PURPOSE:To obtain the titled composition consisting of a polypeptide, a basic amino acid and/or a salt thereof as an absorption promoter and a water- absorbing solid base suitable for nasal mucosa. CONSTITUTION:A powdery composition for nasotracheal administration containing a physiologically active polypeptide (e.g. peptide hormone such as calcitonin, insulin, growth hormone, etc., physiologically active protein, enzyme protein, vaccine, etc.), a basic amino acid (e.g. arginine, histidine, lysine, etc.) and/or a salt thereof as an absorption promoter and a water-absorbing solid base (e.g. water-absorbing and slightly water-soluble cellulose, starch, crosslinked vinyl polymer, etc.) suitable for application to nasal mucosa. The concentration of the amino acid is preferably 0.1-30wt% based on sum of the composition. The composition can be directly made into powder in unit administration form.
PURPOSE:To obtain the curable material which yields cured matter having high hardness when respective components of materials are kneaded and rested to cause hydration self-curing and to obtain the cured matter converting to apatite having excellent bioaffinity upon lapse of time and which allows a change in curing time within a range from 5 minutes to about several hours at a relatively low temp. around the temp. of a living body by adjusting the amt. of the acids to be added, the amt. of a neutralizer, etc. CONSTITUTION:This curable material contains hydration self-curing calcium phosphate contg. calcium which is a curable material having a self-curing property and phosphorus at Ca/P=1.3 to 2.0 ratio by atomic ratio, at least one kind of the neutralizers selected from a fluoride hardly soluble in water, at least one kind of the fluorides soluble in water selected from sodium fluoride, acidic sodium fluoride, potassium fluoride and acidic potassium fluoride, acid, sodium hydroxide, and postassium hydroxide and water, and has (na+K)/F=0.2 to 40 ratio by respective atoms of the sodium, postassium and fluorine of at least one kind of the above-mentioned fluorides soluble in water and the above- mentioned neutralizers.
The use of a proteosome based composition for treating a neurological disease or disorder. The proteosome based composition comprises; (a)(i) proteosomes obtained from a gram-negative bacterium and (ii) an endogenous lipopolysaccharide; or (b)(i) proteosomes obtained from a gram-negative bacterium and (ii) an exogenous lipopolysaccharide. The proteosome composition can be in conjunction with or formulated with a Glatiramer Acetate composition. In preferred embodiments the proteosome is from Nesseria meningitides and the lipopolysaccharide is from Shigella flexneri. The neurological diseases to be treated are those resulting from amyloid-beta accumulation and amyloid plaques, such as Alzheimer's disease. (62) Divided Out of 552075
Chronic kidney disease (CKD) and, in particular, chronic haemodialysis (HD) patients have a high risk of developing sleep disorders and executive dysfunction. Sleep disorders have a prevalence of 75 % in the haemodialysed population and several causes are behind their occurrence: sympatho-vagal imbalances, low melatonin production, vitamin D deficiency, altered cerebral haemodynamics and haemodialysis-induced vascular stress. Executive dysfunction affects about 55 % of haemodialysis patients. The causes can be ascribed to dysfunctions of the frontal lobes. HD patients show frontal brain atrophy and reduced brain activity and connectivity of several frontal and prefrontal areas. Sleep quality also has a significant impact on executive functions; inefficient and fragmented sleep reduces the efficiency of executive functions and increases the risk of dementia. Sleep deprivation also alters the connectivity and structure of several frontal areas. Thus, sleep and executive functions seem to be closely linked. Multidisciplinary care of patients with CKD and in HD appears essential to structure preventive interventions, pharmacological and non-pharmacological treatments that can improve sleep quality, preserve the integrity of executive functions and improve their quality of life.
PROBLEM TO BE SOLVED: To obtain the subject bleaching preparation exhibiting an inhibitory effect on melanization, etc., developing a bleaching effect in a short time by including one or more kinds selected from extracts of Glycyrrhiza glaba Linne Var, Silybum marianum Gaertn., Prunus persica Batsch and an extract of wheat embryo bud. SOLUTION: This bleaching preparation contains (A) one or more kinds selected from extracts of (i) Glycyrrhiza glaba Linne Var., (ii) Silybum marianum Gaertn. and (iii) Prunus persica Batsch and (B) an extract of wheat embryo bud. Preferably the preparation contains 0.0001-10 wt.% calculated as a dried solid content of the compound A and 0.0001-10 wt.% content of the component B. For example, oil-soluble Glycyrrhiza glaba Linne Var. essence PT (40) (trade name) and glabridin extract from Glycyrrhiza glaba Linne Var., can be used as the component (i), an extract obtained from the fruit or the whole plant of Silybum marianum Gaertn. with acetone as the component (ii) and an extract obtained from leaves, fruits, seeds, etc., of Prunus persica Batsch with ethanol as the component (iii).  A substance obtained by extracting wheat embryo bud with water, concentrating and filtering can be used as the composition B.
The time to arrest donors after circulatory death is unpredictable and can vary. This leads to variable periods of warm ischemic damage prior to pancreas transplantation. There is little evidence supporting procurement team stand-down times based on donor time to death (TTD). We examined what impact TTD had on pancreas graft outcomes following donors after circulatory death (DCD) simultaneous pancreas-kidney transplantation. Data were extracted from the UK transplant registry from 2014 to 2022. Predictors of graft loss were evaluated using a Cox proportional hazards model. Adjusted restricted cubic spline models were generated to further delineate the relationship between TTD and outcome. Three-hundred-and-seventy-five DCD simultaneous kidney-pancreas transplant recipients were included. Increasing TTD was not associated with graft survival (adjusted hazard ratio HR 0.98, 95% confidence interval 0.68-1.41, P = .901). Increasing asystolic time worsened graft survival (adjusted hazard ratio 2.51, 95% confidence interval 1.16-5.43, P = .020). Restricted cubic spline modeling revealed a nonlinear relationship between asystolic time and graft survival and no relationship between TTD and graft survival. We found no evidence that TTD impacts pancreas graft survival after DCD simultaneous pancreas-kidney transplantation; however, increasing asystolic time was a significant predictor of graft loss. Procurement teams should attempt to minimize asystolic time to optimize pancreas graft survival rather than focus on the duration of TTD.
INTRODUCTION: Recurrent postmenopausal bleeding (PMB) occurs in 6%-25% of postmenopausal women who have experienced a previous episode of PMB. The question of whether recurrent PMB leads to a higher risk of endometrial cancer (EC) in comparison to a single episode of PMB is, however, controversial. Furthermore, little is known about predictive factors for recurrent PMB.
MATERIAL AND METHODS: A multicenter prospective cohort study was conducted over a 5-year period in four hospitals in the Netherlands. Women with PMB undergoing endometrial sampling and aged 40 years and older were included. Occurrence of recurrent PMB was retrospectively determined. Primary outcomes included (1) the incidence of recurrent PMB and (2) differences in pathological findings between patients with a single episode vs recurrent PMB. Secondary outcomes included (1) the association between diagnosis of benign polyps at first PMB and pathological findings at recurrent PMB and (2) factors predictive for recurrent PMB.
RESULTS: A total of 437 women with PMB were included, of whom 360 were at risk of recurrent PMB. With a median follow-up of 61 months (IQR (Interquartile range) 44-73), 26.4% experienced recurrent PMB. Patients with recurrent PMB were more often diagnosed with benign polyps (34.7% vs. 25.1%, p-value 0.015) and less frequently with a malignancy (5.3% vs. 17.8%, p-value 0.015), compared to patients with a single episode of PMB. Benign polyps at initial PMB were not associated with a (pre)malignancy at recurrence (OR 4.16, 95% CI 0.75-23.03). Predictive factors for recurrent PMB included use of hormone replacement therapy (HRT) (OR 3.32, 95% CI 1.64-6.72), and benign polyps at initial PMB (OR 1.80, 95% CI 1.07-3.04).
CONCLUSIONS: Recurrent PMB is common in women with a previous episode of PMB. Compared to patients with a single episode of PMB, patients with recurrent PMB and benign histological outcomes at accurate workup during their first episode were less often diagnosed with malignancies and more frequently with benign polyps. Benign polyps at first PMB are predictive for recurrent PMB, but not for a higher risk of (pre)malignancy.
The invention relates to a radioimmuno-pharmacon for treating the HIV-1 infection. The disadvantages of standard HIV therapies are that the medicaments currently used must be taken daily in large quantities (approx. 30 tablets per day), in accordance with a strict timetable and for the rest of the patient's life, and that they cause numerous side effects. In addition, conventional medicaments only reduce the replication of the virus. They do not eliminate the host cells infected with HIV and therefore do not cure the HIV infection. The inventive radioimmuno-pharmacon consists of a monoclonal antibody and a radionuclide for eliminating HIV-replicating cells in patients infected with HIV-1 in vivo after the virus burden has been reduced with an antiretroviral therapy and optionally, with the added protection of a host cell transplantation and with medicamentous protection of thyroid activity. According to the invention, this radioimmuno-pharmacon is administered to the HIV-1-infected patient intravenously, once or in several cycles. It targets and inflicts lasting damage on the host cells in order to eliminate as near to all of them as possible. The aim is to heal the HIV infection or at least slow down the progression of the disease.
This study is a single (Part A) and multiple (Part B) dose study. Following informed consent and screening, 10 eligible subjects will receive a single dose of Thetanix or placebo in the clinic. A Safety Review Committee will review the safety data up to Day 7 from these first ten subjects and determine if it is appropriate to continue into Part B in which 10 subjects will receive 15 doses of Thetanix or placebo in a twice daily dosing regimen over 7.5 days. In both parts of the study, 8 of the 10 subjects will randomly receive Thetanix and 2 subjects will randomly receive placebo. Each dose consists of three capsules. Subjects in Part B will receive the first and last dose in the clinic and will take 13 doses at home. While at home, subjects will be required to answer questions about their health, record their body temperature and when they take the capsules in an electronic diary. Subjects developing a fever will undergo further assessments, including blood cultures. Subjects will provide stool samples for analysis of microbiota and faecal calprotectin.
Administration of levobupivacaine 0,25% 0,5 ml/kg through the hiatus sacralis lege artis. IV administration of dexamethasone 0,5mg/kg (max. 5mg) during standard anaesthetic management.
Patients will be informed about the study procedures during a follow-up consultation or an hospitalization in a Physical and Rehabilitation Medicine Unit. If they give their informed consent to participate in the study, an investigator will randomize them into one of the 2 arms of the study. This study consists of 3 visits. The first visit (inclusion) is planned at day 0, the second visit 10 weeks later and the third 3 months after day 0. A patient who is randomized in the experimental arm will have to follow 10 weeks of rehabilitation of the inspiratory muscles at home between first and second visit. During this period, investigators will call these patients once a week to assess the compliance with the rehabilitation. The patients who have been randomized in the control group will not follow this rehabilitation program.